Tags

Type your tag names separated by a space and hit enter

Targeting the complement system for the management of retinal inflammatory and degenerative diseases.
Eur J Pharmacol. 2016 Sep 15; 787:94-104.EJ

Abstract

The retina, an immune privileged tissue, has specialized immune defense mechanisms against noxious insults that may exist in diseases such as age-related macular degeneration (AMD), diabetic retinopathy (DR), uveoretinitis and glaucoma. The defense system consists of retinal innate immune cells (including microglia, perivascular macrophages, and a small population of dendritic cells) and the complement system. Under normal aging conditions, retinal innate immune cells and the complement system undergo a low-grade activation (parainflammation) which is important for retinal homeostasis. In disease states such as AMD and DR, the parainflammatory response is dysregulated and develops into detrimental chronic inflammation. Complement activation in the retina is an important part of chronic inflammation and may contribute to retinal pathology in these disease states. Here, we review the evidence that supports the role of uncontrolled or dysregulated complement activation in various retinal degenerative and angiogenic conditions. We also discuss current strategies that are used to develop complement-based therapies for retinal diseases such as AMD. The potential benefits of complement inhibition in DR, uveoretinitis and glaucoma are also discussed, as well as the need for further research to better understand the mechanisms of complement-mediated retinal damage in these disease states.

Authors+Show Affiliations

Centre for Experimental Medicine, School of Medicine, Dentistry & Biomedical Sciences, Queen's University Belfast, UK. Electronic address: heping.xu@qub.ac.uk.Centre for Experimental Medicine, School of Medicine, Dentistry & Biomedical Sciences, Queen's University Belfast, UK. Electronic address: m.chen@qub.ac.uk.

Pub Type(s)

Journal Article
Review

Language

eng

PubMed ID

26948311

Citation

Xu, Heping, and Mei Chen. "Targeting the Complement System for the Management of Retinal Inflammatory and Degenerative Diseases." European Journal of Pharmacology, vol. 787, 2016, pp. 94-104.
Xu H, Chen M. Targeting the complement system for the management of retinal inflammatory and degenerative diseases. Eur J Pharmacol. 2016;787:94-104.
Xu, H., & Chen, M. (2016). Targeting the complement system for the management of retinal inflammatory and degenerative diseases. European Journal of Pharmacology, 787, 94-104. https://doi.org/10.1016/j.ejphar.2016.03.001
Xu H, Chen M. Targeting the Complement System for the Management of Retinal Inflammatory and Degenerative Diseases. Eur J Pharmacol. 2016 Sep 15;787:94-104. PubMed PMID: 26948311.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Targeting the complement system for the management of retinal inflammatory and degenerative diseases. AU - Xu,Heping, AU - Chen,Mei, Y1 - 2016/03/03/ PY - 2015/10/27/received PY - 2016/01/12/revised PY - 2016/03/01/accepted PY - 2016/3/8/entrez PY - 2016/3/8/pubmed PY - 2017/3/7/medline KW - Age-related macular degeneration KW - Complement KW - Diabetic retinopathy KW - Glaucoma KW - Inflammation KW - Treatment KW - Uveoretinitis SP - 94 EP - 104 JF - European journal of pharmacology JO - Eur J Pharmacol VL - 787 N2 - The retina, an immune privileged tissue, has specialized immune defense mechanisms against noxious insults that may exist in diseases such as age-related macular degeneration (AMD), diabetic retinopathy (DR), uveoretinitis and glaucoma. The defense system consists of retinal innate immune cells (including microglia, perivascular macrophages, and a small population of dendritic cells) and the complement system. Under normal aging conditions, retinal innate immune cells and the complement system undergo a low-grade activation (parainflammation) which is important for retinal homeostasis. In disease states such as AMD and DR, the parainflammatory response is dysregulated and develops into detrimental chronic inflammation. Complement activation in the retina is an important part of chronic inflammation and may contribute to retinal pathology in these disease states. Here, we review the evidence that supports the role of uncontrolled or dysregulated complement activation in various retinal degenerative and angiogenic conditions. We also discuss current strategies that are used to develop complement-based therapies for retinal diseases such as AMD. The potential benefits of complement inhibition in DR, uveoretinitis and glaucoma are also discussed, as well as the need for further research to better understand the mechanisms of complement-mediated retinal damage in these disease states. SN - 1879-0712 UR - https://www.unboundmedicine.com/medline/citation/26948311/Targeting_the_complement_system_for_the_management_of_retinal_inflammatory_and_degenerative_diseases_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S0014-2999(16)30112-1 DB - PRIME DP - Unbound Medicine ER -